list of glp-1 agonist medications receptor drugs A schematic overview agonists: classification, drug The GLP-1 Agonists and Obesity: – novo nordisk glp-1 receptor GLP-1 Agonists - Endocrinology Advisor

qPCR was performed on immunoprecipitated DNA using SYBR Green Supermix

States that have recently cut or restricted GLP-1 coverage for weight loss include: North Carolina (ended coverage October 2025) California, New Hampshire, and South Carolina (ending coverage January 2026) Pennsylvania (restricting coverage to non-weight-loss indications) Michigan (limiting to morbidly obese patients only) The BALANCE model will open to state Medicaid agencies as early as May 2026, which could eventually bring more uniform pricing and access

Ongoing medical guidance is recommended before tapering off

The injection is a convenient solution for individuals with a busy lifestyle as well

(Separate analyses of 2025 Medicare Advantage plans, premiums and benefits are also available.) ( See Methods box for details on this analysis.) Overall, KFF analysis shows that the market for Part D coverage remains robust based on the overall number of plan options, but the number of sponsors, plans, and enrollees in the stand-alone PDP market has trended downward over time, while the MA-PD market remains stable and continues to experience steady enrollment growth